Business Wire

AMCS

12.5.2022 09:32:12 CEST | Business Wire | Press release

Share
AMCS to Acquire Quentic – Partners for a Green Future

AMCS, a leading global supplier of integrated cloud-based software and vehicle technology for the environmental, utilities, waste, recycling, and resource industries, announced today that it has entered into an agreement to acquire Quentic, one of the leading solution providers of Software as a Service for EHSQ and ESG management, for an undisclosed amount. The transaction is subject to regulatory approval and is expected to close in the coming weeks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005027/en/

In connection with AMCS’ acquisition of Quentic, Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) is making a new equity investment in AMCS alongside new equity investments from existing investors Insight Partners, Ireland Strategic Investment Fund (ISIF), and Highland Europe.

AMCS continues strong growth globally
With this acquisition, AMCS will be positioned to broaden its expertise in the environmental services industry globally and continue to expand its customer base. With a combined 4,000 customers supported by over 1,000 employees, AMCS is on a trajectory to achieve run rate revenues greater than €180m by the end of the year.

AMCS extends environmental services offering across a wider industry
AMCS and Quentic are now positioned to provide more advanced digital solutions to a wider industry, which will enrich their customers’ operations and impact the environment for a healthier, cleaner, and more sustainable world.

Leveraging expertise to fuel a net zero carbon future
Combining forces is an important step for both companies as they leverage the expertise from each organization and jointly lead the way for added competence in the market. Managing resources from cradle-to-cradle has become a key responsibility for businesses across all industries. The integration of AMCS and Quentic enables customers on both sides to benefit from a wide range of solutions that support end-to-end standardization and optimization of business processes to increase efficiencies, streamline operations and work toward a safe and sustainable future.

“AMCS and Quentic are very aligned with the mission to drive an environmentally sustainable future”, says Jimmy Martin, CEO of AMCS. “A net zero carbon future depends on a very connected and circular approach across the supply chain. We are thrilled to bring the technology from Quentic into the AMCS portfolio of solutions and can now move forward with a focus on influencing the entire supply chain, offering smarter outcomes from automating and digitizing their businesses -- reducing waste as much as possible.”

Quentic adds 15 years of EHSQ excellence to AMCS’ portfolio
CEO Markus Becker, COO Sebastian Mönnich and CTO Hardy Menzel founded Quentic, formerly EcoIntense, in 2007 to provide software for environmental management. Today, Quentic provides a holistic and modular Software as a Service solution to manage all tasks and processes related to environmental, health, safety, and quality management (EHSQ) as well as corporate responsibility-related areas in environment, social and governance (ESG).

“We have built Quentic on the values of making a meaningful contribution to people, society and the environment”, Markus Becker, CEO of Quentic said. “Therefore, we are excited to have found a partner in AMCS who fully aligns with our mission to digitally empower companies across the globe to manage people, business and environmental processes sustainably at all levels. Together with AMCS, the Quentic management team will continue to shape the future.”

About AMCS

AMCS is headquartered in Limerick, Ireland with offices in North America, Europe, and Australia employing over 800 people across 12 countries. AMCS is a global leader of integrated software and vehicle technology for the environmental, recycling, and resource industries and offers optimization solutions to the broader transport and logistics market. AMCS helps over 3,000 customers in 22 countries to reduce their operating costs, increase asset utilization, optimize margins, and improve customer service. Their enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world.

About Quentic

Quentic is one of the leading solution providers of Software as a Service (SaaS) for EHSQ and ESG management. The Quentic platform comprises ten individually combinable modules and offers an ideal way for companies to manage Health & Safety, Risks & Audits, Incidents & Observations, Hazardous Chemicals, Control of Work, Legal Compliance, Online Instructions, Processes, Environmental Management and Sustainability.

The company is headquartered in Berlin, Germany, and employs more than 250 people. Branch offices are located in Germany, Austria, Switzerland, Finland, Sweden, Denmark, Belgium, the Netherlands, France, Spain and Italy.

About Clearlake Capital Group, L.P.

Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with management teams by providing patient, long-term capital to businesses that can benefit from Clearlake’s operational improvement approach, O.P.S.® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has over $72 billion of assets under management, and its senior investment principals have led or co-led over 400 investments. The firm is headquartered in Santa Monica, CA with affiliates in Dallas, TX, London, UK and Dublin, Ireland. More information is available at www.clearlake.com and on Twitter @Clearlake.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye